SVB Securities lowered shares of VectivBio (NASDAQ:VECT – Get Rating) from an outperform rating to a market perform rating in a report published on Tuesday, The Fly reports.
A number of other research analysts also recently commented on the stock. Piper Sandler raised their target price on shares of VectivBio from $23.00 to $25.00 and gave the company an overweight rating in a research report on Thursday, April 20th. Credit Suisse Group downgraded VectivBio from an outperform rating to a neutral rating in a research report on Monday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, VectivBio presently has an average rating of Moderate Buy and a consensus price target of $24.33.
VectivBio Stock Up 1.8 %
Shares of NASDAQ VECT opened at $16.50 on Tuesday. The company has a quick ratio of 9.14, a current ratio of 9.14 and a debt-to-equity ratio of 0.05. The business has a fifty day simple moving average of $9.94 and a two-hundred day simple moving average of $8.89. VectivBio has a twelve month low of $4.25 and a twelve month high of $16.60.
Institutional Investors Weigh In On VectivBio
VectivBio Company Profile
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy.
- Get a free copy of the StockNews.com research report on VectivBio (VECT)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for VectivBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VectivBio and related companies with MarketBeat.com's FREE daily email newsletter.